|
Dynavax Technologies Corporation - Company Profile Snapshot
| Company Profile: |
Dynavax Technologies Corporation |
| Ticker: |
DVAX |
| Exchanges: |
NAS |
| 2008 Sales: |
37,094,000 |
| Major Industry: |
Miscellaneous |
| Sub Industry: |
Medical Services |
| Country: |
UNITED STATES |
| Employees: |
155 |
Business Description
Dynavax Technologies Corporation. The Company's principal activity is to discover, develop and commercialize TLR-9 agonist-based products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases. The clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. The products in pipeline includes: TOLAMBA, a ragweed allergy immunotherapeutic, currently in major large-scale clinical trial in ragweed allergic adults and in a supportive trial in ragweed allergic children; HEPLISAV, a hepatitis B vaccine, currently in a Phase 3 clinical trial; SUPERVAX, a hepatitis B vaccine; a cancer therapy currently in a Phase 2 clinical trial in non-Hodgkins lymphoma; an asthma immunotherapeutic that has shown preliminary safety and pharmacology in a Phase 2a clinical trial and preclinical programs in hepatitis B and C therapy.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
